Clinical Trial Assessing the HERV-W Env Antagonist GNbAC1 for Efficacy in MS

NCT02782858 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

270

Enrollment

INDUSTRY

Sponsor class

Conditions

Multiple Sclerosis, Relapsing-Remitting

Interventions

DRUG: GNbAC1
DRUG: Placebo

Sponsor

GeNeuro SA

Collaborators

[object Object]
[object Object]
[object Object]